North America Diabetes Drugs Market Size (2024 - 2029)

The North America Diabetes Drugs Market is projected to experience growth over the forecast period, driven by factors such as the increasing prevalence of diabetes and the impact of the COVID-19 pandemic. The pandemic highlighted the importance of diabetic drugs in managing complications associated with COVID-19, particularly for patients with weakened immune systems. This has led to a rise in remote care and the removal of regulatory barriers, further influencing the market's expansion. The market's growth is also supported by the need for continuous management of blood glucose levels among diabetes patients, which is crucial for preventing serious health complications.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research North America Diabetes Pharmaceutical Market Market Size

Market Size of North America Diabetes Drugs Industry

North America Diabetes Drugs Market Summary
Study Period 2019- 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 35.82 Billion
Market Size (2029) USD 42.36 Billion
CAGR (2024 - 2029) 3.58 %

Major Players

North America Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

North America Diabetes Drugs Market Analysis

The North America Diabetes Drugs Market size is estimated at USD 35.82 billion in 2024, and is expected to reach USD 42.36 billion by 2029, growing at a CAGR of 3.58% during the forecast period (2024-2029).

The COVID-19 pandemic positively impacted the North America Diabetes Drugs Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. In North America, till April 2022, the United States was having the highest COVID cases around 82 million, the country also registered the highest death rate. Pandemic emergency has created a rise in remote care from both patients and providers and removed many long-standing regulatory barriers.

The North American region had witnessed an alarming increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to treat diabetes mellitus by lowering the glucose level in the blood. The North America Diabetes Drugs Market is segmented into drugs (insulin drugs (basal or long-acting insulins, bolus or fast-acting insulins, traditional human insulins, and biosimilar insulins), oral anti-diabetic drugs (Biguanides, Alpha-Glucosidase inhibitors, Dopamine D2 receptor agonist, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, and Meglitinides), non-insulin injectable drugs (GLP-1 receptor agonists and Amylin Analogue), and combination drugs (insulin combinations and oral combinations)) and geography (United States, Canada, and Rest of North America). The report offers the value (in USD) and volume (in units) for the above segments.

Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Ozempic (Semaglutide)
Amylin Analogue
Symlin (Pramlintide)
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Geography
United States
Canada
Rest of North America
Need A Different Region Or Segment?
Customize Now

North America Diabetes Drugs Market Size Summary

The North America Diabetes Drugs Market is poised for significant growth, driven by the increasing prevalence of diabetes and the rising demand for effective treatment options. The market is characterized by a diverse range of diabetic drugs designed to stabilize and control blood glucose levels, with oral anti-diabetic drugs expected to lead the growth trajectory. The COVID-19 pandemic has further underscored the importance of these drugs, as individuals with diabetes faced heightened risks, prompting a surge in demand. The market landscape is semi-consolidated, with major players like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca dominating the scene. These companies are actively engaging in strategic mergers and acquisitions, alongside the introduction of innovative therapies, to maintain their competitive edge and expand their market share.

The United States holds a substantial portion of the market, reflecting the high incidence of diabetes, particularly type 2, among its population. The market's expansion is supported by favorable insurance coverage for diabetes medications, including Medicare, which recognizes these drugs as medically necessary. The introduction of new drug classes, such as dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors, has further enriched the treatment landscape. Additionally, ongoing clinical trials and regulatory approvals, like those for Eli Lilly's Mounjaro and Oramed's oral insulin capsule, highlight the continuous innovation within the market. These developments, coupled with the growing awareness and need for diabetes management, are expected to drive the market's growth over the forecast period.

Explore More

North America Diabetes Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Insulins

      1. 2.1.1 Basal or Long Acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Biosimilar Insulins

        1. 2.1.4.1 Insulin Glargine Biosimilars

        2. 2.1.4.2 Human Insulin Biosimilars

    2. 2.2 Oral Anti-diabetic drugs

      1. 2.2.1 Biguanides

        1. 2.2.1.1 Metformin

      2. 2.2.2 Alpha-Glucosidase Inhibitors

        1. 2.2.2.1 Alpha-Glucosidase Inhibitors

      3. 2.2.3 Dopamine D2 receptor agonist

        1. 2.2.3.1 Bromocriptin

      4. 2.2.4 SGLT-2 inhibitors

        1. 2.2.4.1 Invokana (Canagliflozin)

        2. 2.2.4.2 Jardiance (Empagliflozin)

        3. 2.2.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.2.4.4 Suglat (Ipragliflozin)

      5. 2.2.5 DPP-4 inhibitors

        1. 2.2.5.1 Onglyza (Saxagliptin)

        2. 2.2.5.2 Tradjenta (Linagliptin)

        3. 2.2.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.2.5.4 Galvus (Vildagliptin)

      6. 2.2.6 Sulfonylureas

        1. 2.2.6.1 Sulfonylureas

      7. 2.2.7 Meglitinides

        1. 2.2.7.1 Meglitinides

    3. 2.3 Non-Insulin Injectable drugs

      1. 2.3.1 GLP-1 receptor agonists

        1. 2.3.1.1 Victoza (Liraglutide)

        2. 2.3.1.2 Byetta (Exenatide)

        3. 2.3.1.3 Bydureon (Exenatide)

        4. 2.3.1.4 Trulicity (Dulaglutide)

        5. 2.3.1.5 Lyxumia (Lixisenatide)

        6. 2.3.1.6 Ozempic (Semaglutide)

      2. 2.3.2 Amylin Analogue

        1. 2.3.2.1 Symlin (Pramlintide)

    4. 2.4 Combination drugs

      1. 2.4.1 Insulin combinations

        1. 2.4.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.4.2 Oral Combinations

        1. 2.4.2.1 Janumet (Sitagliptin and Metformin)

    5. 2.5 Geography

      1. 2.5.1 United States

      2. 2.5.2 Canada

      3. 2.5.3 Rest of North America

North America Diabetes Drugs Market Size FAQs

The North America Diabetes Drugs Market size is expected to reach USD 35.82 billion in 2024 and grow at a CAGR of 3.58% to reach USD 42.36 billion by 2029.

In 2024, the North America Diabetes Drugs Market size is expected to reach USD 35.82 billion.

North America Diabetes Drugs Market Report Snapshots

North America Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)